Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis

Oncotype DX is a commercial assay frequently used for making chemotherapy decisions in estrogen receptor (ER)-positive breast cancers. The result is reported as a recurrence score ranging from 0 to 100, divided into low-risk (<18), intermediate-risk (18–30), and high-risk (≥31) categories. Our pi...

Descripción completa

Detalles Bibliográficos
Autores principales: Klein, Molly E, Dabbs, David J, Shuai, Yongli, Brufsky, Adam M, Jankowitz, Rachel, Puhalla, Shannon L, Bhargava, Rohit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3647116/
https://www.ncbi.nlm.nih.gov/pubmed/23503643
http://dx.doi.org/10.1038/modpathol.2013.36

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3647116/
https://www.ncbi.nlm.nih.gov/pubmed/23503643
http://dx.doi.org/10.1038/modpathol.2013.36

Ejemplares similares